Evolution of liver function during immune checkpoint inhibitor treatment for hepatocellular carcinoma.
United European Gastroenterol J
; 2024 Jul 11.
Article
en En
| MEDLINE
| ID: mdl-38990728
ABSTRACT
BACKGROUND AND AIMS:
Deterioration of liver function is a leading cause of death in patients with advanced hepatocellular carcinoma (HCC). We evaluated the impact of immune checkpoint inhibitor (ICI)-treatment on liver function and outcomes.METHOD:
HCC patients receiving ICIs or sorafenib between 04/2003 and 05/2024 were included. Liver function (assessed by Child-Pugh score [CPS]) was evaluated at the start of ICI-treatment (baseline, BL) and 3 and 6 months thereafter. A ≥1 point change in CPS was defined as deterioration (-) or improvement (+), while equal CPS points were defined as stable (=).RESULTS:
Overall, 182 ICI-treated patients (66.8 ± 11.8 years; cirrhosis n = 134, 74%) were included. At BL, median CPS was 5 (IQR 5-6; CPS-A 147, 81%). After 3 months, liver function improved/stabilized in 102 (56%) and deteriorated in 61 (34%) patients, while 19 (10%) patients deceased/had missing follow-up (d/noFU). Comparable results were observed at 6 months (+/= n = 82, 45%; - n = 55, 30%; d/noFU n = 45, 25%). In contrast, 54 (34%) and 33 (21%) out of 160 sorafenib patients achieved improvement/stabilization at 3 and 6 months, respectively. Radiological response was linked to CPS improvement/stabilization at 6 months (responders vs. non-responders, 73% vs. 50%; p = 0.007). CPS improvement/stabilization at 6 months was associated with better overall survival following landmark analysis (6 months +/= 28.4 [95% CI 18.7-38.1] versus - 14.2 [95% CI 10.3-18.2] months; p < 0.001). Of 35 ICI-patients with CPS-B at BL, improvement/stabilization occurred in 16 (46%) patients, while 19 (54%) patients deteriorated/d/noFU at 3 months. Comparable results were observed at 6 months (CPS +/= 14, 40%, - 8, 23%). Importantly, 6/35 (17%) and 9/35 (26%) patients improved from CPS-B to CPS-A at 3 and 6 months.CONCLUSION:
Radiological response to ICI-treatment was associated with stabilization or improvement in liver function, which correlated with improved survival, even in patients with Child-Pugh class B at baseline.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Idioma:
En
Revista:
United European Gastroenterol J
Año:
2024
Tipo del documento:
Article
País de afiliación:
Austria
Pais de publicación:
Reino Unido